Olaparib
利普卓(Lynparza)
A PARP inhibitor pill that exploits BRCA-mutation weakness in cancer cells.
At a glance
China price
Verified pricing is not currently available.
NRDL (national insurance)
In NRDL for ovarian maintenance.
Regulatory status
NMPA approved (2018, ); NRDL (2020)
What this meansSupported by a credible secondary source but not yet independently confirmed against a primary source.
SourceNo independent source on file.
NotesApproval status from public regulatory reporting.
What it treats
BRCA-mutated ovarian cancer (incl. maintenance); BRCA-mutated breast and prostate cancer.
Sources & verification
No independent source is currently on file. We have not independently verified this information.
Reader discussion
Public comments about Olaparib. Discussion is not medical advice, and a comment is not an endorsement or a verified fact. Open the full forum.